ClinicalTrials.gg
CompletedNCT07254728Updated Apr 15, 2026Results posted

A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

A Phase 1 interventional study of VXA-G1.1-NN and VXA-G2.4-NS in Norovirus Infections, sponsored by Vaxart. Completed at 5 sites in South Africa. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Vaxart · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Oct 2023, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of an oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and to assess the short-term immunogenicity of oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and its association with the immunogenicity response in breastmilk.

02

Conditions studied

  • Norovirus Infections

Keywords

  • Healthy participants
  • VXA-G1.1-NN
  • VXA-G2.4-NS
03

In context

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

This study's enrollment of 76 is close to the median of 71 across 18 interventional studies indexed under Caliciviridae Infections.

Browse Caliciviridae Infections studies →

Lead sponsor

Vaxart is the lead sponsor of 23 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Lactating females aged ≥ 18 years at the time of enrolment and their breastfed infants aged >30 days to 11 months of age at the time of the participants' study drug administration.
  2. In stable and good general health, without significant medical illness, based on medical history, physical examination (including vital signs), and clinical judgment of the investigator.
  3. Lactating females willing and able to provide which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  4. Lactating females who are willing to provide consent for their breastfed infant.
  5. Negative pregnancy tests at screening and prior to dose on Day 1.
  6. Available for all planned visits and tele-health appointments, and ability to comply with all study-related evaluations (including but not limited to having the ability and willingness to swallow multiple small enteric-coated tablets per study dose, express/pump breastmilk, and collect infant stool samples).
  7. Plan to continue breastfeeding as the main source of the infant's nutrition for at least 1 month (longer is preferred with goal of 6 months post dose if possible) from the time of study drug administration. Exclusive breastfeeding is acceptable but not necessary.
  8. The nursing infant is the product of a singleton pregnancy AND does not have any of the following:

    1. Any abnormality that may interfere with breastfeeding or milk absorption
    2. Active infection (may be included if the infection resolves and the participant is re-assessed during the screening period)
    3. Infant has any other medical condition or abnormality that, in the opinion of the investigator, could compromise the infant's appropriate inclusion in this study including interference with the interpretation of study results (such as malabsorption)
    4. One or more documented brief resolved unexplained events (BRUEs)
    5. Extreme prematurity (infants who were born at less than 28 weeks gestation)
    6. 30 days of age or less at the participant's study drug administration OR greater than 11 months of age at the participant's study drug administration
    7. Prior hospitalization that is not exclusively for hyperbilirubinemia requiring phototherapy
    8. Any genetic/metabolic disease
    9. Any chronic illness requiring long term medication
  9. Participants must be willing to use a highly effective form of for 30 days prior to vaccination and until 60 days after the vaccination. Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence (participants using diaphragms must also use condom). The form of contraception must be approved by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Presence of a fever ≥ 38.0°C measured orally at baseline, on Day 1 prior to vaccination. (Assessment may be repeated once during screening period).
  2. Acute disease within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam). (Assessment may be repeated once during screening period).
  3. Participants who have received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration.
  4. Positive (HIV), surface antigen (HBsAg), or virus (HCV) tests at the screening visit.
  5. History of or allergic reaction to any component of the vaccine, including but not limited to fish gelatin.
  6. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
  7. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including the institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline.
  8. History of significant pregnancy-related complications during this pregnancy, including but not limited to pre-eclampsia, eclampsia, or gestational diabetes unless a full resolution is documented.
  9. Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).
  10. Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus type 1 or 2.
  11. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

    a. Any history of:

    i.

    ii. Malabsorption

    iii. Pancreatobiliary disorders

    iv. Inflammatory bowel disease

    v. Irritable bowel disease

    vi. Hiatal hernia

    vii. Surgical resection

    b. History of diagnosis or treatment in past 5 years of:

    i. Esophageal or gastric motility disorder

    ii. Gastroesophageal reflux disease (GERD) - Will allow for participants with a history of pregnancy-related GERD if fully resolved for >3 months and no other history of GERD diagnosis

    iii. Peptic ulcer

    iv. Cholecystectomy

  12. Any condition that resulted in the absence or removal of the spleen.
  13. History of any form of angioedema.
  14. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic.
  15. History of GI bleeding including hematochezia (blood in stool) or melena (black stool).
  16. Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation.
  17. Any of the following history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia:

    1. Family or personal history of bleeding or thrombosis
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments
    3. History of or inflammatory disease
    4. Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening:

    i. Recent surgery other than fully healed cesarean delivery or excision/ of cutaneous lesions

    ii. Immobility (confined to bed or wheelchair for 3 or more successive days)

    iii. Head trauma with loss of consciousness or documented brain injury

    iv. Receipt of anticoagulants for prophylaxis of thrombosis

    v. Recent infection including hospitalization for COVID-19 related illness

  18. Any other condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of a participant taking in the study, would render the participant unable to comply with the protocol, or would interfere with the evaluation of the study endpoints.
  19. Receipt of a licensed vaccine (including any COVID-19 vaccines under Emergency Use Authorization) within 14 days prior to study drug dose or planned administration during the study active period.
  20. Use of antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use during the active study period.
  21. Use of medications known to affect the immune function (including but not limited to systemic , leukotriene modifiers, and Janus kinase [JAK] inhibitors) within 2 weeks before study drug administration or planned use during the active study period.
  22. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the active study period.
  23. Donation or receipt of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period.
  24. Participating in any clinical trial with another investigational product within 30 days prior to the first trial visit or intend to participate in another clinical trial at any time during the conduct of this trial.
  25. Are first-degree relatives of individuals involved in trial conduct.
  26. Positive urine drug screen for drugs of abuse at screening.
  27. Positive alcohol test at screening or baseline.
  28. History of drug, alcohol, or chemical abuse within 1 year of screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Bivalent GII.4/GI.1 Medium Dose Vaccine

    Participants will receive a medium dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.

    Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS

  • Experimental
    Bivalent GII.4/GI.1 High Dose Vaccine

    Participants will receive a high dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.

    Biological: VXA-G1.1-NN · Biological: VXA-G2.4-NS

  • Placebo comparator
    Placebo

    Participants will receive matching placebo orally on Day 1.

    Biological: Placebo Tablets

Interventions

  • BiologicalVXA-G1.1-NN

    Oral tablets.

    Also known as: GI.1

  • BiologicalVXA-G2.4-NS

    Oral tablets.

    Also known as: GII.4

  • BiologicalPlacebo Tablets

    Oral tablets.

06

What researchers measure

Primary outcomes

  1. Number of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial Dose

    Solicited symptoms of reactogenicity were predefined adverse events (AEs) for which the participant was specifically questioned, and which were noted by the participant in their solicited symptom diary, including: fever (any temperature 100°F or higher), headache, myalgia (muscle pain), abdominal pain, anorexia (defined as not eating), nausea, vomiting, diarrhea, and malaise/fatigue. The severity of each solicited symptom of reactogenicity was graded by the participant as mild, moderate, severe or life-threatening.

    Time frame: 1 week post study dose (8 days)

  2. Number of Participants (Mothers) With Unsolicited Treatment-emergent Adverse Events (TEAEs)

    TEAEs:AEs that began after start of an investigational product or an already present event that worsens in intensity or frequency following intervention.An AE considered serious (SAE) if,in view of Investigator or Sponsor,it resulted in death,life-threatening AE,inpatient hospitalization/prolongation of hospitalization,persistent or significant incapacity or disability disrupting normal life functions,congenital anomaly/birth defect,or an important medical event which based upon medical judgment may have jeopardized participant and required intervention to prevent 1 of outcomes.AESIs:serious/non-serious AEs of scientific and medical concern with potential immune mediated conditions and events associated with thrombosis and thrombocytopenia.NOCI:diagnosis post-enrollment and vaccination of new chronic medical condition,including those controllable by medication.An AE was unsolicited if it did not fulfill conditions prelisted in eCRF in terms of diagnosis/onset window post-vaccination.

    Time frame: 4 weeks post dose (29 days)

  3. Geometric Mean Concentration (GMC) of Serum Viral Protein 1 (VP1) Specific (G1.1) Immunoglobulin A (IgA) on Days 1, 8 and 29

    GMC of serum VP1 specific (G1.1) IgA was measured by Meso Scale Discovery (MSD) assay. Assay was measured in an arbitrary unit per milliliter (AU/mL).

    Time frame: Days 1, 8 and 29

  4. GMC of Serum VP1 Specific (G2.4) IgA on Days 1, 8 and 29

    GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.

    Time frame: Days 1, 8 and 29

  5. Geometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 8

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 8

  6. GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 29

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 29

  7. GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 8

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 8

  8. GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 29

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 29

  9. Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgA

    A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29 and 180

  10. Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgA

    A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29 and 180

  11. GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 1, 8 and 29

    GMC of breastmilk VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in Relative Light Unit per microgram (RLU)/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

    Time frame: Days 1, 8, and 29

  12. GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 1, 8 and 29

    GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

    Time frame: Days 1, 8 and 29

  13. GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 8

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 8

  14. GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 8

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 8

  15. GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 29

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 29

  16. GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 29

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 29

  17. Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G1.1) IgA

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibody compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

  18. Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G2.4) IgA

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

Secondary outcomes

  1. Number of Participants With SAEs, AESIs and NOCIs Through 12 Months Post Dose

    An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset window post-vaccination. An AESIs serious or nonserious) is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor can be appropriate. NOCIs was defined as diagnosis post-enrollment and vaccination of a new medical condition, which is chronic in nature, including those potentially controllable by medication. Only unsolicited SAEs, AESI and NOCIs data was planned to be collected and assessed for the assessment of this OM and solicited SAEs, AESIs and NOCIs was out of the scope of assessment. Participants with unsolicited SAEs, AESIs and NOCIs throughout the trial were reported in this outcome measure.

    Time frame: Up to 12 months

  2. GMC of Serum VP1 Specific (G1.1) IgA on Day 180

    GMC of serum VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in AU/mL.

    Time frame: Day 180

  3. GMC of Serum VP1 Specific (G2.4) IgA on Day 180

    GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.

    Time frame: Day 180

  4. GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 180

  5. GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 180

  6. GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 60 and 180

    GMC of breastmilkVP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

    Time frame: Days 60 and 180

  7. GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 60 and 180

    GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

    Time frame: Days 60 and 180

  8. GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 60

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 60

  9. GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 60

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 60

  10. GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 180

  11. GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Day 180

  12. GMC of Serum VP1 Specific (G1.1) Immunoglobulin G (IgG) on Days 1, 8, 29, and 180

    GMC of serum VP1 specific (G1.1) IgG was measured by MSD assay. Assay is measured in AU/mL.

    Time frame: Days 1, 8, 29, and 180

  13. GMC of Serum VP1 Specific (G2.4) IgG on Days 1, 8, 29, and 180

    GMC of serum VP1 specific (G2.4) IgG was measured by MSD assay. Assay is measured in AU/mL.

    Time frame: Days 1, 8, 29 and 180

  14. GMFR of Serum VP1 Specific (G1.1) IgG From Day 1 to Days 8, 29, and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: From Day 1 to Days 8, 29, and 180

  15. GMFR of Serum VP1 Specific (G2.4) IgG From Day 1 to Days 8, 29, and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: From Day 1 to Days 8, 29, and 180

  16. Number of Participants Who Achieved a 2-fold, 3-fold, and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgG

    A 2, 3, and 4-fold rise represents the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, and 180

  17. Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgG

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, and 180

  18. Geometric Mean Titer (GMT) of Serum Blocking Titers 50 (BT50) (G1.1) on Days 1, 8, 29, and 180

    Serum BT50 (G1.1) through 6 months after trial drug dose was measured by histo-blood group antigen (HBGA) assay. Blood samples were collected at different timepoints throughout the trial.

    Time frame: Days 1, 8, 29, and 180

  19. GMT of Serum BT50 (G2.4) on Days 1, 8, 29, and 180

    Serum BT50 (G2.4) through 6 months after trial drug dose was measured by HBGA assay. Blood samples were collected at different timepoints throughout the trial.

    Time frame: Days 1, 8, 29, and 180

  20. GMFR of Serum BT50 (G1.1) From Day 1 to Days 8, 29 and 180

    The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 8, 29, and 180

  21. GMFR of Serum BT50 (G2.4) From Day 1 to Days 8, 29 and 180

    The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 8, 29 and 180

  22. Number of Participants Who Achieved 2-fold, 3-fold, and 4-fold GMT Rise in Serum VP1 Specific (G1.1) IgG

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, and 180

  23. Number of Participants With 2-fold, 3-fold and 4-fold GMT Rise in Serum VP1 Specific IgG (G2.4)

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, and 180

Other outcomes

  1. GMC of Nasal VP1 Specific (G1.1) IgA

    GMC of nasal VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in microgram per milligram (µg/mg).

    Time frame: Days 1, 8, 29, 60, and 180

  2. GMC of Nasal VP1 Specific (G2.4) IgA

    GMC of nasal VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

    Time frame: Days 1, 8, 29, 60, and 180

  3. GMFR of Nasal VP1 Specific (GI.I) IgA From Day 1 to Days 8, 29, 60 and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 8, 29, 60 and 180

  4. GMFR of Nasal VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60 and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 8, 29, 60 and 180

  5. Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G1.1)

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

  6. Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G2.4)

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

  7. GMC of Saliva VP1 Specific (G1.1) IgA

    GMC of saliva VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

    Time frame: Days 1, 8, 29, 60, and 180

  8. GMC of Saliva VP1 Specific (G2.4) IgA

    GMC of saliva VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

    Time frame: Days 1, 8, 29, 60, and 180

  9. GMFR of Saliva VP1 Specific (G1.1) IgA From Day 1 to Days 8, 29, 60 and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 8, 29, 60, and 180

  10. GMFR of Saliva VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60, and 180

    GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: From Day 1 to Days 8, 29, 60, and 180

  11. Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G1.1)

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

  12. Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G2.4)

    A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29, 60 and 180

  13. GMC of Infant Stool VP1 Specific (G1.1) IgA

    GMC of infant stool VP1 specific (G1.1) IgA was measured by Enzyme-linked immunosorbent assay (ELISA). Assay is measured in mg/gm.

    Time frame: Days 1, 29 and 60

  14. GMC of Infant Stool VP1 Specific (G2.4) IgA

    GMC of infant stool VP1 specific (G2.4) IgA was measured by ELISA. Assay is measured in mg/gm.

    Time frame: Days 1, 29 and 60

  15. GMFR of Infant Stool VP1 Specific (G1.1) IgA From Day 1 to Days 29 and 60

    GMFR was measured by ELISA. The fold rise was calculated per participant (infant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 29 and 60

  16. GMFR of Infant Stool VP1 Specific (G2.4) IgA From Day 1 to Days 29 and 60

    GMFR was measured by ELISA. The fold rise was calculated per infant (participant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

    Time frame: Day 1 to Days 29 and 60

  17. Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G1.1)

    A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 29 and 60

  18. Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G2.4)

    A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

    Time frame: Days 1, 8, 29 and 60

  19. Number of Participants With Norovirus Acute Gastroenteritis

    Data was not collected for this outcome measure.

    Time frame: From first dose up to Day 365

07

Results

Posted Apr 15, 2026

Participant flow

A total of 76 mother participants were enrolled between October 2023 and December 2024 in South Africa.

Participant flow — Overall Study
MilestoneArm 1 Medium Bivalent DoseArm 2 High Bivalent DoseArm 3 Placebo
Started303016
Mothers started303016
Infants started303016
Completed262912
Not completed414
Withdrew: Lost to follow-up212
Withdrew: Withdrawal by subject202

Outcome measures

PrimaryNumber of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial Dose

Solicited symptoms of reactogenicity were predefined adverse events (AEs) for which the participant was specifically questioned, and which were noted by the participant in their solicited symptom diary, including: fever (any temperature 100°F or higher), headache, myalgia (muscle pain), abdominal pain, anorexia (defined as not eating), nausea, vomiting, diarrhea, and malaise/fatigue. The severity of each solicited symptom of reactogenicity was graded by the participant as mild, moderate, severe or life-threatening.

Time frame:
1 week post study dose (8 days)
Reported as:
Count of participants · Participants
Number of Participants (Mothers) With Any Solicited Symptoms of Reactogenicity for 1 Week Following Trial Dose
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Mild1585
Moderate151
Severe000
Life-threatening000
PrimaryNumber of Participants (Mothers) With Unsolicited Treatment-emergent Adverse Events (TEAEs)

TEAEs:AEs that began after start of an investigational product or an already present event that worsens in intensity or frequency following intervention.An AE considered serious (SAE) if,in view of Investigator or Sponsor,it resulted in death,life-threatening AE,inpatient hospitalization/prolongation of hospitalization,persistent or significant incapacity or disability disrupting normal life functions,congenital anomaly/birth defect,or an important medical event which based upon medical judgment may have jeopardized participant and required intervention to prevent 1 of outcomes.AESIs:serious/non-serious AEs of scientific and medical concern with potential immune mediated conditions and events associated with thrombosis and thrombocytopenia.NOCI:diagnosis post-enrollment and vaccination of new chronic medical condition,including those controllable by medication.An AE was unsolicited if it did not fulfill conditions prelisted in eCRF in terms of diagnosis/onset window post-vaccination.

Time frame:
4 weeks post dose (29 days)
Reported as:
Count of participants · Participants
Number of Participants (Mothers) With Unsolicited Treatment-emergent Adverse Events (TEAEs)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
TEAEs332
SAEs000
AESIs000
NOCIs000
PrimaryGeometric Mean Concentration (GMC) of Serum Viral Protein 1 (VP1) Specific (G1.1) Immunoglobulin A (IgA) on Days 1, 8 and 29

GMC of serum VP1 specific (G1.1) IgA was measured by Meso Scale Discovery (MSD) assay. Assay was measured in an arbitrary unit per milliliter (AU/mL).

Time frame:
Days 1, 8 and 29
Reported as:
Geometric mean · AU/mL
Geometric Mean Concentration (GMC) of Serum Viral Protein 1 (VP1) Specific (G1.1) Immunoglobulin A (IgA) on Days 1, 8 and 29
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 11050560.6 ± 1.31625693.1 ± 1.41209786.5 ± 1.2
Day 83007539.8 ± 1.44608961.1 ± 1.31291836.6 ± 1.3
Day 292065978.9 ± 1.32822260.3 ± 1.31421687.4 ± 1.3
PrimaryGMC of Serum VP1 Specific (G2.4) IgA on Days 1, 8 and 29

GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.

Time frame:
Days 1, 8 and 29
Reported as:
Geometric mean · AU/mL
GMC of Serum VP1 Specific (G2.4) IgA on Days 1, 8 and 29
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 1217289.1 ± 1.4233243.3 ± 1.4211741.7 ± 1.3
Day 8414338.2 ± 1.3667484.3 ± 1.4235517.7 ± 1.3
Day 29350427.7 ± 1.4491546.9 ± 1.3260989.1 ± 1.4
PrimaryGeometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 8

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 8
Reported as:
Geometric least squares mean · fold rise
Geometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 8
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Geometric Mean Fold Rise (GMFR) From Day 1 to Day 8 of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 82.7 ± 1.23.0 ± 1.21.1 ± 1.3
PrimaryGMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 29

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 29
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 29
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 291.8 ± 1.21.9 ± 1.21.1 ± 1.3
PrimaryGMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 8

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 8
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 8
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 81.9 ± 1.22.9 ± 1.21.1 ± 1.2
PrimaryGMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 29

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 29
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 29
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 291.5 ± 1.12.1 ± 1.11.1 ± 1.2
PrimaryNumber of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgA

A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29 and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgA
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold12191
Day 8: 3-fold11141
Day 8: 4-fold10131
Day 29: 2-fold9172
Day 29: 3-fold892
Day 29: 4-fold642
Day 180: 2-fold432
Day 180: 3-fold321
Day 180: 4-fold211
PrimaryNumber of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgA

A 2, 3, 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29 and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgA
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold11171
Day 8: 3-fold8111
Day 8: 4-fold7101
Day 29: 2-fold9132
Day 29: 3-fold571
Day 29: 4-fold351
Day 180: 2-fold242
Day 180: 3-fold142
Day 180: 4-fold122
PrimaryGMC of Breastmilk VP1 Specific (G1.1) IgA on Days 1, 8 and 29

GMC of breastmilk VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in Relative Light Unit per microgram (RLU)/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

Time frame:
Days 1, 8, and 29
Reported as:
Geometric mean · RLU/µg of total IgA
GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 1, 8 and 29
RLU/µg of total IgAArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 126300.4 ± 1.226309.0 ± 1.329393.5 ± 1.2
Day 836747.1 ± 1.242476.5 ± 1.230427.5 ± 1.2
Day 2952017.9 ± 1.361663.9 ± 1.231963.7 ± 1.2
PrimaryGMC of Breastmilk VP1 Specific (G2.4) IgA on Days 1, 8 and 29

GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

Time frame:
Days 1, 8 and 29
Reported as:
Geometric mean · RLU/µg of total IgA
GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 1, 8 and 29
RLU/µg of total IgAArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 175811.2 ± 1.340270.6 ± 1.379636.1 ± 1.5
Day 883208.0 ± 1.367097.9 ± 1.387120.3 ± 1.5
Day 29114825.2 ± 1.3107289.5 ± 1.478850.3 ± 1.5
PrimaryGMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 8

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 8
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 8
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 81.4 ± 1.11.6 ± 1.11.1 ± 1.2
PrimaryGMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 8

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 8 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 8
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 8
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 81.1 ± 1.11.6 ± 1.11.1 ± 1.2
PrimaryGMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 29

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 29
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 29
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 292.0 ± 1.22.3 ± 1.21.1 ± 1.3
PrimaryGMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 29

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 29 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 29
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 29
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 291.5 ± 1.22.7 ± 1.21.0 ± 1.3
PrimaryNumber of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G1.1) IgA

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibody compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G1.1) IgA
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold6110
Day 8: 3-fold470
Day 8: 4-fold340
Day 29: 2-fold10161
Day 29: 3-fold6111
Day 29: 4-fold671
Day 60: 2-fold8121
Day 60: 3-fold670
Day 60: 4-fold550
Day 180: 2-fold662
Day 180: 3-fold542
Day 180: 4-fold531
PrimaryNumber of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G2.4) IgA

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieve a 2-fold, 3-fold and 4-fold GMC Rise in Breastmilk VP1 Specific (G2.4) IgA
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold3120
Day 8: 3-fold160
Day 8: 4-fold030
Day 29: 2-fold7150
Day 29: 3-fold3100
Day 29: 4-fold2100
Day 60: 2-fold7120
Day 60: 3-fold4110
Day 60: 4-fold480
Day 180: 2-fold2111
Day 180: 3-fold170
Day 180: 4-fold150
SecondaryNumber of Participants With SAEs, AESIs and NOCIs Through 12 Months Post Dose

An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset window post-vaccination. An AESIs serious or nonserious) is one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor can be appropriate. NOCIs was defined as diagnosis post-enrollment and vaccination of a new medical condition, which is chronic in nature, including those potentially controllable by medication. Only unsolicited SAEs, AESI and NOCIs data was planned to be collected and assessed for the assessment of this OM and solicited SAEs, AESIs and NOCIs was out of the scope of assessment. Participants with unsolicited SAEs, AESIs and NOCIs throughout the trial were reported in this outcome measure.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AESIs and NOCIs Through 12 Months Post Dose
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
SAEs000000
AESIs000000
NOCIs000000
SecondaryGMC of Serum VP1 Specific (G1.1) IgA on Day 180

GMC of serum VP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in AU/mL.

Time frame:
Day 180
Reported as:
Geometric mean · AU/mL
GMC of Serum VP1 Specific (G1.1) IgA on Day 180
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMC of Serum VP1 Specific (G1.1) IgA on Day 1801276858.6 ± 1.41344498.0 ± 1.31187410.4 ± 1.3
SecondaryGMC of Serum VP1 Specific (G2.4) IgA on Day 180

GMC of serum VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in AU/mL.

Time frame:
Day 180
Reported as:
Geometric mean · AU/mL
GMC of Serum VP1 Specific (G2.4) IgA on Day 180
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMC of Serum VP1 Specific (G2.4) IgA on Day 180230142.5 ± 1.3264313.3 ± 1.4286679.6 ± 1.4
SecondaryGMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Serum VP1 Specific (G1.1) IgA From Day 1 to Day 1801.1 ± 1.21.0 ± 1.21.0 ± 1.3
SecondaryGMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Serum VP1 Specific (G2.4) IgA From Day 1 to Day 1801.0 ± 1.11.3 ± 1.11.3 ± 1.2
SecondaryGMC of Breastmilk VP1 Specific (G1.1) IgA on Days 60 and 180

GMC of breastmilkVP1 specific (G1.1) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

Time frame:
Days 60 and 180
Reported as:
Geometric mean · RLU/µg of total IgA
GMC of Breastmilk VP1 Specific (G1.1) IgA on Days 60 and 180
RLU/µg of total IgAArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 6038202.5 ± 1.339691.9 ± 1.222119.3 ± 1.2
Day 18029484.2 ± 1.329964.5 ± 1.223367.0 ± 1.3
SecondaryGMC of Breastmilk VP1 Specific (G2.4) IgA on Days 60 and 180

GMC of breastmilk VP1 specific (G2.4) IgA was measured by MSD assay. Assay is measured in RLU/µg of total IgA which is a normalized measure used to quantify the specific binding of IgA antibodies to norovirus VLPs (measured in RLU) relative to the total amount of IgA protein present in a breast milk.

Time frame:
Days 60 and 180
Reported as:
Geometric mean · RLU/µg of total IgA
GMC of Breastmilk VP1 Specific (G2.4) IgA on Days 60 and 180
RLU/µg of total IgAArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 6091060.2 ± 1.369170.5 ± 1.358705.8 ± 1.5
Day 18062361.5 ± 1.362051.1 ± 1.459187.9 ± 1.5
SecondaryGMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 60

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 60
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 60
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 601.5 ± 1.21.6 ± 1.20.8 ± 1.3
SecondaryGMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 60

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 60 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 60
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 60
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 601.3 ± 1.21.6 ± 1.20.8 ± 1.3
SecondaryGMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G1.1) IgA From Day 1 to Day 1801.1 ± 1.21.1 ± 1.20.8 ± 1.3
SecondaryGMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Day 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Day 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
GMFR of Breastmilk VP1 Specific (G2.4) IgA From Day 1 to Day 1800.8 ± 1.21.5 ± 1.20.8 ± 1.2
SecondaryGMC of Serum VP1 Specific (G1.1) Immunoglobulin G (IgG) on Days 1, 8, 29, and 180

GMC of serum VP1 specific (G1.1) IgG was measured by MSD assay. Assay is measured in AU/mL.

Time frame:
Days 1, 8, 29, and 180
Reported as:
Geometric mean · AU/mL
GMC of Serum VP1 Specific (G1.1) Immunoglobulin G (IgG) on Days 1, 8, 29, and 180
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 13397392.0 ± 1.31964195.4 ± 1.32765544.4 ± 1.4
Day 84985139.4 ± 1.23678526.6 ± 1.33109431.7 ± 1.3
Day 296548114.2 ± 1.36113406.5 ± 1.23386464.1 ± 1.4
Day 1804590720.0 ± 1.33044433.6 ± 1.23753633.6 ± 1.4
SecondaryGMC of Serum VP1 Specific (G2.4) IgG on Days 1, 8, 29, and 180

GMC of serum VP1 specific (G2.4) IgG was measured by MSD assay. Assay is measured in AU/mL.

Time frame:
Days 1, 8, 29 and 180
Reported as:
Geometric mean · AU/mL
GMC of Serum VP1 Specific (G2.4) IgG on Days 1, 8, 29, and 180
AU/mLArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 1893913.0 ± 1.3641462.6 ± 1.2605754.7 ± 1.4
Day 8962779.9 ± 1.31013436.9 ± 1.2679718.6 ± 1.3
Day 29916270.9 ± 1.31261314.2 ± 1.2673043.6 ± 1.3
Day 180740190.3 ± 1.3808781.1 ± 1.2690756.2 ± 1.3
SecondaryGMFR of Serum VP1 Specific (G1.1) IgG From Day 1 to Days 8, 29, and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
From Day 1 to Days 8, 29, and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G1.1) IgG From Day 1 to Days 8, 29, and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
From Day 1 to Day 81.6 ± 1.11.8 ± 1.11.1 ± 1.2
From Day 1 to Day 292.1 ± 1.22.8 ± 1.21.2 ± 1.2
From Day 1 to Day 1801.5 ± 1.21.5 ± 1.21.4 ± 1.2
SecondaryGMFR of Serum VP1 Specific (G2.4) IgG From Day 1 to Days 8, 29, and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
From Day 1 to Days 8, 29, and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum VP1 Specific (G2.4) IgG From Day 1 to Days 8, 29, and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
From Day 1 to Day 81.1 ± 1.11.6 ± 1.11.1 ± 1.1
From Day 1 to Day 291.1 ± 1.11.9 ± 1.11.0 ± 1.2
From Day 1 to Day 1800.9 ± 1.21.2 ± 1.21.1 ± 1.2
SecondaryNumber of Participants Who Achieved a 2-fold, 3-fold, and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgG

A 2, 3, and 4-fold rise represents the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a 2-fold, 3-fold, and 4-fold GMC Rise in Serum VP1 Specific (G1.1) IgG
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold6101
Day 8: 3-fold461
Day 8: 4-fold451
Day 29: 2-fold9192
Day 29: 3-fold6142
Day 29: 4-fold5102
Day 180: 2-fold8115
Day 180: 3-fold573
Day 180: 4-fold453
SecondaryNumber of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgG

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a 2-fold, 3-fold and 4-fold GMC Rise in Serum VP1 Specific (G2.4) IgG
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold081
Day 8: 3-fold041
Day 8: 4-fold031
Day 29: 2-fold3111
Day 29: 3-fold071
Day 29: 4-fold041
Day 180: 2-fold293
Day 180: 3-fold132
Day 180: 4-fold022
SecondaryGeometric Mean Titer (GMT) of Serum Blocking Titers 50 (BT50) (G1.1) on Days 1, 8, 29, and 180

Serum BT50 (G1.1) through 6 months after trial drug dose was measured by histo-blood group antigen (HBGA) assay. Blood samples were collected at different timepoints throughout the trial.

Time frame:
Days 1, 8, 29, and 180
Reported as:
Geometric mean · geometric mean titer
Geometric Mean Titer (GMT) of Serum Blocking Titers 50 (BT50) (G1.1) on Days 1, 8, 29, and 180
geometric mean titerArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 161.6 ± 1.357.4 ± 1.380.5 ± 1.5
Day 8120.3 ± 1.3108.4 ± 1.478.8 ± 1.4
Day 29175.4 ± 1.3158.7 ± 1.483.1 ± 1.5
Day 180106.4 ± 1.368.1 ± 1.380.5 ± 1.5
SecondaryGMT of Serum BT50 (G2.4) on Days 1, 8, 29, and 180

Serum BT50 (G2.4) through 6 months after trial drug dose was measured by HBGA assay. Blood samples were collected at different timepoints throughout the trial.

Time frame:
Days 1, 8, 29, and 180
Reported as:
Geometric mean · geometric mean titer
GMT of Serum BT50 (G2.4) on Days 1, 8, 29, and 180
geometric mean titerArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 169.1 ± 1.365.2 ± 1.242.0 ± 1.3
Day 862.3 ± 1.268.3 ± 1.233.1 ± 1.2
Day 2976.0 ± 1.394.4 ± 1.240.6 ± 1.3
Day 18049.4 ± 1.256.6 ± 1.240.3 ± 1.3
SecondaryGMFR of Serum BT50 (G1.1) From Day 1 to Days 8, 29 and 180

The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 8, 29, and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum BT50 (G1.1) From Day 1 to Days 8, 29 and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
From Day 1 to Day 81.9 ± 1.21.9 ± 1.21.0 ± 1.3
From Day 1 to Day 292.7 ± 1.22.7 ± 1.21.0 ± 1.3
From Day 1 to Day 1801.6 ± 1.21.3 ± 1.21.1 ± 1.3
SecondaryGMFR of Serum BT50 (G2.4) From Day 1 to Days 8, 29 and 180

The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 8, 29 and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Serum BT50 (G2.4) From Day 1 to Days 8, 29 and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
From Day 1 to Day 80.9 ± 1.11.1 ± 1.10.7 ± 1.1
From Day 1 to Day 291.1 ± 1.11.5 ± 1.10.8 ± 1.1
From Day 1 to Day 1800.7 ± 1.10.9 ± 1.10.8 ± 1.1
SecondaryNumber of Participants Who Achieved 2-fold, 3-fold, and 4-fold GMT Rise in Serum VP1 Specific (G1.1) IgG

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, and 180
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 2-fold, 3-fold, and 4-fold GMT Rise in Serum VP1 Specific (G1.1) IgG
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold14171
Day 8: 3-fold890
Day 8: 4-fold890
Day 29: 2-fold21232
Day 29: 3-fold10121
Day 29: 4-fold10121
Day 180: 2-fold13134
Day 180: 3-fold553
Day 180: 4-fold553
SecondaryNumber of Participants With 2-fold, 3-fold and 4-fold GMT Rise in Serum VP1 Specific IgG (G2.4)

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, and 180
Reported as:
Count of participants · Participants
Number of Participants With 2-fold, 3-fold and 4-fold GMT Rise in Serum VP1 Specific IgG (G2.4)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 8: 2-fold480
Day 8: 3-fold110
Day 8: 4-fold110
Day 29: 2-fold5111
Day 29: 3-fold150
Day 29: 4-fold150
Day 180: 2-fold251
Day 180: 3-fold001
Day 180: 4-fold001
Other pre-specifiedGMC of Nasal VP1 Specific (G1.1) IgA

GMC of nasal VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in microgram per milligram (µg/mg).

Time frame:
Days 1, 8, 29, 60, and 180
Reported as:
Geometric mean · µg/mg
GMC of Nasal VP1 Specific (G1.1) IgA
µg/mgArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 10.2 ± 1.20.2 ± 1.30.2 ± 1.2
Day 80.3 ± 1.20.3 ± 1.20.2 ± 1.2
Day 290.3 ± 1.30.3 ± 1.20.2 ± 1.3
Day 600.2 ± 1.20.2 ± 1.20.1 ± 1.3
Day 1800.1 ± 1.20.2 ± 1.20.1 ± 1.3
Other pre-specifiedGMC of Nasal VP1 Specific (G2.4) IgA

GMC of nasal VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

Time frame:
Days 1, 8, 29, 60, and 180
Reported as:
Geometric mean · µg/mg
GMC of Nasal VP1 Specific (G2.4) IgA
µg/mgArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers
Day 10.1 ± 1.30.1 ± 1.30.1 ± 1.2
Day 80.2 ± 1.30.1 ± 1.30.1 ± 1.3
Day 290.2 ± 1.30.2 ± 1.30.1 ± 1.4
Day 600.1 ± 1.20.1 ± 1.30.0 ± 1.3
Day 1800.1 ± 1.20.1 ± 1.30.1 ± 1.3
Other pre-specifiedGMFR of Nasal VP1 Specific (GI.I) IgA From Day 1 to Days 8, 29, 60 and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 8, 29, 60 and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Nasal VP1 Specific (GI.I) IgA From Day 1 to Days 8, 29, 60 and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
From Day 1 to Day 81.8 ± 1.21.3 ± 1.20.7 ± 1.2
From Day 1 to Day 291.7 ± 1.21.2 ± 1.20.9 ± 1.3
From Day 1 to Day 600.8 ± 1.20.8 ± 1.20.5 ± 1.3
From Day 1 to Day 1800.7 ± 1.20.7 ± 1.20.7 ± 1.3
Other pre-specifiedGMFR of Nasal VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60 and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 8, 29, 60 and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Nasal VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60 and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
From Day 1 to Day 81.3 ± 1.21.3 ± 1.20.7 ± 1.2
From Day 1 to Day 291.7 ± 1.21.7 ± 1.20.7 ± 1.3
From Day 1 to Day 600.6 ± 1.20.8 ± 1.20.4 ± 1.3
From Day 1 to Day 1800.5 ± 1.20.7 ± 1.20.5 ± 1.3
Other pre-specifiedNumber of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G1.1)

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G1.1)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 8: 2-fold1271
Day 8: 3-fold640
Day 8: 4-fold420
Day 29: 2-fold1091
Day 29: 3-fold450
Day 29: 4-fold440
Day 60: 2-fold560
Day 60: 3-fold350
Day 60: 4-fold340
Day 180: 2-fold751
Day 180: 3-fold531
Day 180: 4-fold421
Other pre-specifiedNumber of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G2.4)

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Nasal VP1 Specific IgA (G2.4)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 8: 2-fold770
Day 8: 3-fold340
Day 8: 4-fold140
Day 29: 2-fold10120
Day 29: 3-fold570
Day 29: 4-fold360
Day 60: 2-fold380
Day 60: 3-fold340
Day 60: 4-fold120
Day 180: 2-fold450
Day 180: 3-fold340
Day 180: 4-fold230
Other pre-specifiedGMC of Saliva VP1 Specific (G1.1) IgA

GMC of saliva VP1 specific (G1.1) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

Time frame:
Days 1, 8, 29, 60, and 180
Reported as:
Geometric mean · µg/mg
GMC of Saliva VP1 Specific (G1.1) IgA
µg/mgArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 10.1 ± 1.30.2 ± 1.20.1 ± 1.2
Day 80.1 ± 1.20.2 ± 1.20.2 ± 1.2
Day 290.2 ± 1.20.2 ± 1.20.2 ± 1.2
Day 600.2 ± 1.20.2 ± 1.20.2 ± 1.1
Day 1800.2 ± 1.20.2 ± 1.20.2 ± 1.1
Other pre-specifiedGMC of Saliva VP1 Specific (G2.4) IgA

GMC of saliva VP1 specific (G2.4) IgA from lactating mothers was measured by MSD assay. Assay is measured in µg/mg.

Time frame:
Days 1, 8, 29, 60, and 180
Reported as:
Geometric mean · µg/mg
GMC of Saliva VP1 Specific (G2.4) IgA
µg/mgArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 10.1 ± 1.20.1 ± 1.20.1 ± 1.2
Day 80.1 ± 1.20.1 ± 1.20.1 ± 1.1
Day 290.1 ± 1.20.1 ± 1.20.1 ± 1.2
Day 600.1 ± 1.20.1 ± 1.20.1 ± 1.2
Day 1800.1 ± 1.20.1 ± 1.20.1 ± 1.2
Other pre-specifiedGMFR of Saliva VP1 Specific (G1.1) IgA From Day 1 to Days 8, 29, 60 and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 8, 29, 60, and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Saliva VP1 Specific (G1.1) IgA From Day 1 to Days 8, 29, 60 and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
From Day 1 to Day 81.2 ± 1.11.2 ± 1.11.1 ± 1.1
From Day 1 to Day 291.5 ± 1.11.2 ± 1.11.1 ± 1.1
From Day 1 to Day 601.7 ± 1.11.2 ± 1.11.4 ± 1.2
From Day 1 to Day 1801.5 ± 1.21.2 ± 1.21.2 ± 1.2
Other pre-specifiedGMFR of Saliva VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60, and 180

GMFR was measured by MSD assay. The fold rise was calculated per participant by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
From Day 1 to Days 8, 29, 60, and 180
Reported as:
Geometric least squares mean · fold rise
GMFR of Saliva VP1 Specific (G2.4) IgA From Day 1 to Days 8, 29, 60, and 180
fold riseArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
From Day 1 to Day 81.1 ± 1.11.4 ± 1.11.1 ± 1.1
From Day 1 to Day 291.4 ± 1.11.6 ± 1.11.0 ± 1.1
From Day 1 to Day 601.5 ± 1.11.2 ± 1.11.1 ± 1.1
From Day 1 to Day 1801.1 ± 1.11.2 ± 1.11.1 ± 1.2
Other pre-specifiedNumber of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G1.1)

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G1.1)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 8: 2-fold850
Day 8: 3-fold530
Day 8: 4-fold010
Day 29: 2-fold1062
Day 29: 3-fold500
Day 29: 4-fold200
Day 60: 2-fold1264
Day 60: 3-fold1051
Day 60: 4-fold610
Day 180: 2-fold1155
Day 180: 3-fold831
Day 180: 4-fold531
Other pre-specifiedNumber of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G2.4)

A 2, 3, and 4-fold rise represented the participants with at least a 2, 3, or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29, 60 and 180
Reported as:
Count of participants · Participants
Number of Participants With 2-fold, 3-fold and 4-fold GMC Rise in Saliva VP1 Specific IgA (G2.4)
ParticipantsArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: Mothers: Mothers
Day 8: 2-fold290
Day 8: 3-fold110
Day 8: 4-fold100
Day 29: 2-fold890
Day 29: 3-fold340
Day 29: 4-fold320
Day 60: 2-fold990
Day 60: 3-fold430
Day 60: 4-fold300
Day 180: 2-fold653
Day 180: 3-fold141
Day 180: 4-fold020
Other pre-specifiedGMC of Infant Stool VP1 Specific (G1.1) IgA

GMC of infant stool VP1 specific (G1.1) IgA was measured by Enzyme-linked immunosorbent assay (ELISA). Assay is measured in mg/gm.

Time frame:
Days 1, 29 and 60
Reported as:
Geometric mean · milligram per gram (mg/gm)
GMC of Infant Stool VP1 Specific (G1.1) IgA
milligram per gram (mg/gm)Arm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
Day 10.0 ± 1.20.0 ± 1.40.1 ± 1.3
Day 290.1 ± 1.40.1 ± 1.30.1 ± 1.3
Day 600.1 ± 1.30.1 ± 1.40.0 ± 1.5
Other pre-specifiedGMC of Infant Stool VP1 Specific (G2.4) IgA

GMC of infant stool VP1 specific (G2.4) IgA was measured by ELISA. Assay is measured in mg/gm.

Time frame:
Days 1, 29 and 60
Reported as:
Geometric mean · mg/gm
GMC of Infant Stool VP1 Specific (G2.4) IgA
mg/gmArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
Day 10.1 ± 1.70.0 ± 1.40.1 ± 1.7
Day 290.1 ± 1.60.2 ± 1.50.1 ± 1.7
Day 600.1 ± 1.60.1 ± 1.60.0 ± 1.7
Other pre-specifiedGMFR of Infant Stool VP1 Specific (G1.1) IgA From Day 1 to Days 29 and 60

GMFR was measured by ELISA. The fold rise was calculated per participant (infant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 29 and 60
Reported as:
Geometric least squares mean · fold rise
GMFR of Infant Stool VP1 Specific (G1.1) IgA From Day 1 to Days 29 and 60
fold riseArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
From Day 1 to Day 293.2 ± 1.31.8 ± 1.31.4 ± 1.5
From Day 1 to Day 602.8 ± 1.31.5 ± 1.31.1 ± 1.4
Other pre-specifiedGMFR of Infant Stool VP1 Specific (G2.4) IgA From Day 1 to Days 29 and 60

GMFR was measured by ELISA. The fold rise was calculated per infant (participant) by dividing the least square mean value on Days 8, 29 and 180 with least square mean value at baseline (Day 1).

Time frame:
Day 1 to Days 29 and 60
Reported as:
Geometric least squares mean · fold rise
GMFR of Infant Stool VP1 Specific (G2.4) IgA From Day 1 to Days 29 and 60
fold riseArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
From Day 1 to Day 291.4 ± 1.43.3 ± 1.40.7 ± 1.6
From Day 1 to Day 601.1 ± 1.31.9 ± 1.30.7 ± 1.5
Other pre-specifiedNumber of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G1.1)

A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 29 and 60
Reported as:
Count of participants · Participants
Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G1.1)
ParticipantsArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
Day 29: 2-fold17153
Day 29: 3-fold11112
Day 29: 4-fold991
Day 60: 2-fold15124
Day 60: 3-fold1172
Day 60: 4-fold1151
Other pre-specifiedNumber of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G2.4)

A 2, 3 and 4-fold rise represented the participants (infants) with at least a 2, 3 or 4-fold rise in antibodies compared to pre-vaccination dosing Baseline (Day 1).

Time frame:
Days 1, 8, 29 and 60
Reported as:
Count of participants · Participants
Number of Infants With 2-fold, 3-fold and 4-fold GMC Rise in Infant Stool VP1 Specific IgA (G2.4)
ParticipantsArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
Day 29: 2-fold12151
Day 29: 3-fold7130
Day 29: 4-fold6120
Day 60: 2-fold12122
Day 60: 3-fold691
Day 60: 4-fold571
Other pre-specifiedNumber of Participants With Norovirus Acute Gastroenteritis

Data was not collected for this outcome measure.

Time frame:
From first dose up to Day 365
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

Adverse events

Collected over From first dose up to 365 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 Medium Bivalent Dose: Mothers0/30 (0%)0/30 (0%)16/30 (53.3%)
Arm 2 High Bivalent Dose: Mothers0/30 (0%)0/30 (0%)13/30 (43.3%)
Arm 3 Placebo: Mothers0/16 (0%)0/16 (0%)6/16 (37.5%)
Arm 4 Medium Bivalent Dose: Infants0/30 (0%)0/30 (0%)0/30 (0%)
Arm 5 High Bivalent Dose: Infants0/30 (0%)0/30 (0%)0/30 (0%)
Arm 6 Placebo: Infants0/16 (0%)0/16 (0%)0/16 (0%)
Most frequent other events
Most frequent other events
EventArm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: Infants
HeadacheNervous system disorders6/308/304/160/300/300/16
DiarrhoeaGastrointestinal disorders6/304/301/160/300/300/16
NauseaGastrointestinal disorders5/306/301/160/300/300/16
Malaise/FatigueGeneral disorders2/304/302/160/300/300/16
Abdominal painGastrointestinal disorders1/302/302/160/300/300/16
MyalgiaMusculoskeletal and connective tissue disorders3/302/300/160/300/300/16
AnorexiaMetabolism and nutrition disorders0/302/301/160/300/300/16
FeverGeneral disorders2/302/300/160/300/300/16

Baseline characteristics

Participants included both mothers and infants. Here, the overall number of participants analyzed represents the total number of mothers and infants.

Age, Customized
Age, Customized(Participants)Arm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: InfantsTotal
30 days to 11 months00030301676
18-65 years30301600076
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: InfantsTotal
Female30301615196116
Male00015111036
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: InfantsTotal
Race303016303016152
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1 Medium Bivalent Dose: MothersArm 2 High Bivalent Dose: MothersArm 3 Placebo: MothersArm 4 Medium Bivalent Dose: InfantsArm 5 High Bivalent Dose: InfantsArm 6 Placebo: InfantsTotal
Ethnicity — Black or African American292715292715142
Ethnicity — Others13113110
08

Study locations

5 sites
  • WITS RHI Research Centre
    Hillbrow, 2001, South Africa
  • Progress Clinical Research Unit
    Honeydew, 2040, South Africa
  • Newtown Clinical Research Centre
    Johannesburg, 2001, South Africa
  • Trident Clinical
    Kimberley, 8301, South Africa
  • FCRN Clinical Trials Centre (Pty) Ltd
    Vereeniging, 1935, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Dec 2024, 13 months.

Results were first posted in Apr 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Oct 27, 2023
Primary completionActual
Dec 13, 2024
CompletionActual
Dec 13, 2024
Results first posted
Apr 15, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07254728
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Oct 27, 2023
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024
Results posted
Apr 15, 2026
Last update
Apr 15, 2026

Study contacts

Medical Director
study director · Vaxart, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion